<DOC>
	<DOCNO>NCT02440854</DOCNO>
	<brief_summary>This non-interventional study include representative sample patient locally advance metastatic NSCLC harbor Epidermal Growth Factor Receptor ( EGFR ) -mutations Greece . Eligible NSCLC patient , physician decide initiate treatment study medication ( afatinib , GIOTRIF® ) treat accord local prescribing information standard medical practice term visit frequency type assessment perform . The study investigate impact GIOTRIF ( Afatinib ) patient ' disease-related symptom burden Health-Related Quality Life ( HRQoL ) real world clinical set Greece.The Average Symptom Burden Index ( ASBI ) score Lung Cancer Symptom Scale ( LCSS ) eligible patient , 6 month therapy , analyze . The overall study duration period expect 48 month , include 36-month enrollment period minimum 12-month follow-up period .</brief_summary>
	<brief_title>Evaluate Impact Afatinib Quality Life Symptom Burden Greek Subjects With Advanced NSCLC Routine Patient Care Settings</brief_title>
	<detailed_description>Study Design :</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Inclusion criterion : Adult outpatient ( 18 year old ) either gender ; Histologically cytologically confirm locally advance metastatic ( IIIB/IV ) NSCLC histological type activate EGFR mutation ( ) accord local laboratory EGFR testing ; EGFR tyrosine kinase inhibitor ( TKI ) naive patient ; Patients decision prescribe therapy afatinib ( GIOTRIF® ) accord locally approve product 's summary product characteristic ( SmPC ) already take prior enrolment study ; assignment patient therapeutic strategy decide advance study protocol fall within current practice prescription afatinib clearly separate physician decision include patient current study ; Patients must able willing provide write informed consent comply requirement study protocol ; Exclusion criterion : Patients initiated treatment Afatinib 7 day prior enrolment study ; Patients meet contraindication administration study drug accord approve SmPC ; Receipt investigational agent within 30 day 5 halflives investigational agent ( whichever longer ) commencement therapy afatinib</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>